{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.98","upperLimit":"37.88","value":"28.3"}]}],"title":"End of Induction period Ia"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.89","upperLimit":"62.60","value":"52.8"}]}],"title":"End of Induction period Ib"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.12","upperLimit":"80.02","value":"71.7"}]}],"title":"End of Consolidation period"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"MRD was by real-time qPCR for clone-specific immunoglobulin and T-cell receptor gene rearrangements (IG/TCR). Participants were declared as MRD negative if the MRD level is undetectable providing the assay lower limit of quantification is at least 0.1%","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents newly diagnosed with Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL) treated with standard multiagent chemotherapy and Dasatinib (either in tablets or Powder For Oral Suspension (PFOS)) at a dose of 60 mg/m2 daily.","id":"OG000","title":"Dasatinib Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to End of Induction Period Ia (up to 5 weeks) or Ib (up to 9 weeks) or End of Consolidation Period (up to 22 weeks)","title":"Percentage of Participants Negative for Minimal Residual Disease (MRD)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}